Pemafibrate, a new selective PPARα modulator, was recommended for treating PBC with dyslipidemia, or for patients with poor response to UDCA monotherapy or bezafibrate plus UDCA combination treatment (141). The gene discussed is PPARA; the disease is primary biliary cholangitis.